Screener
Rhythm Pharmaceuticals, Inc. RYTM Professional service fees
Professional service fees at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Research and development costs | $17,800 | $17,084 |
| Professional fees | 6,626 | 5,827 |
| Payroll related | 14,398 | 22,433 |
| Royalties | 3,005 | 2,870 |
| Sales allowances | 33,071 | 31,564 |
| Other | 5,145 | 4,078 |
| Accrued expenses and other current liabilities | $80,045 | $83,855 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s professional service fees?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported professional service fees of $6.63M in Q1 2026.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s professional service fees.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude